Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics develops bispecific T cell engager therapies for autoimmune diseases and cancer. It last closed at $8.89 on Nov 20, down 1.98% on the day. The next earnings report for CGEM is expected around Tue, Mar 9, 2027. Over its last 8 reports the stock moved an average of 3.1% the session after earnings. Over the last 12 months CGEM insiders bought $0 of stock on the open market and sold $2.6M, according to SEC Form 4 filings.
Key Stats
Last 12 monthsNot reported for this period.
From CGEM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on CGEM
Technical AnalysisPrices may be delayed
The stock is 36% below its 20 day and 65% below its 50 day average. It is 77% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the Pivot S1 at $8.64, and the nearest resistance the Pivot at $9.05.
| RSI (14) | 26.37 | Oversold below 30 | Oversold |
| MACD | -1.72 | Below its signal line | Bearish |
| Stochastic | 6.7 | Near the bottom of its range | Oversold |
| ADX (14) | 36.1 | Trending down | |
| Williams %R | -94.6 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -92.9 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −21.4% | Change over 10 sessions | Bearish |
| ATR (14) | $1.04 | Typical daily range, 11.7% of price |
| RSI (14) | 33.80 | Weak, oversold below 30 | Neutral |
| MACD | -1.16 | Below its signal line | Bearish |
| Stochastic | 3.9 | Near the bottom of its range | Oversold |
| ADX (14) | 23.7 | Weak trend | |
| Williams %R | -97.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -182.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −56.8% | Change over 10 sessions | Bearish |
| ATR (14) | $2.69 | Typical daily range, 30.3% of price |
What happened before
See how CGEM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CGEM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options FlowPrices may be delayed
90DNo whale options trades in CGEM in the last 90 days.
CGEM Institutional Ownership
Full report →- ●85 buying vs 77 selling
- ▼Held by funds -2.2 pts
- ▼Funds holding -2
- ▼Superinvestors: 0 added, 4 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 182 | 184 | −1.1% |
| In funds' top 10 | 3 | 3 | 0.0% |
| Held by funds | 108.2% | 110.5% | −2.3 pts |
| New / increased | 21 / 64 | 29 / 84 | −24.8% |
| Reduced / sold out | 55 / 22 | 47 / 20 | +14.9% |
| Put/call ratio | – | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
CGEM Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 5 | Jennifer MichaelsonChief Scientific Officer | Sale plan | 4,000 | $12.36 | $49K |
| Sep 8 | Jennifer MichaelsonChief Scientific Officer | Sale plan | 8,000 | $21.57 | $173K |
| Aug 13 | Jennifer MichaelsonChief Scientific Officer | Sale plan | 30,000 | $20.26 | $608K |
| Jul 6 | Jennifer MichaelsonChief Scientific Officer | Sale plan | 8,000 | $17.82 | $143K |
| May 5 | Jennifer MichaelsonChief Scientific Officer | Sale plan | 8,000 | $14.62 | $117K |
| Mar 5 | Jennifer MichaelsonChief Scientific Officer | Sale plan | 8,000 | $15.68 | $125K |
From SEC Form 4 filings by CGEM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CGEM is in one of them and how their past CGEM trades turned out.
CGEM News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CGEM in an article yet. Here's the latest on the wider market.
- Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- Velinotamig, a BCMAxCD3 T Cell Engager, Achieves Complete Renal Responses and Significantly Reduces Disease Activity in Systemic Lupus Erythematosus in Data Presented at ACR Convergence 2026
- Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68 th ASH Annual Meeting
About Cullinan Therapeutics
Cullinan Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, that develops drug candidates for autoimmune diseases and cancer. Its main programs are bispecific T cell engagers, a type of antibody therapy designed to direct immune T cells against target cells. The company is testing these candidates in clinical trials for lupus, rheumatoid arthritis, Sjögren's disease, and acute myeloid leukemia, and it also works with a partner on an oral lung cancer treatment. Its target patients are people living with these conditions.
- Headquarters
- Cambridge, MA



